{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-257430","form_type":"8-K","ticker":"ANTX","cik":"0001880438","company_name":"AN2 Therapeutics, Inc.","filed_at":"2026-06-04T20:15:49+00:00","discovered_at":"2026-06-04T20:17:00.227710+00:00","generated_at":"2026-06-04T20:51:26.592664+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"AN2 Therapeutics reports 100% parasite elimination in NHP study; Phase 2 for Chagas planned late 2026","bullets":["28-day AN2-502998 treatment in NHPs with chronic T. cruzi infection achieved 100% parasite elimination at human-target exposures, durable for 4 months post-treatment.","Phase 1 FIH study (NCT07024589) in healthy volunteers showed favorable safety, no dose-limiting toxicities, and PK exposures at NHP efficacy thresholds.","Chagas disease affects ~300k in U.S. and ~10M globally; no FDA-approved treatments for adults with chronic disease.","Company plans to initiate Phase 2 proof-of-concept study late 2026; AN2-502998 eligible for FDA Tropical Disease Priority Review Voucher if approved."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-257430","json":"https://secwatch.observer/filing/0001193125-26-257430.json","markdown":"https://secwatch.observer/filing/0001193125-26-257430.md","text":"https://secwatch.observer/filing/0001193125-26-257430.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1880438/000119312526257430/0001193125-26-257430-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1880438/000119312526257430/d247428d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T20:51:26.592664+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}